A phthalocyanine-based photosensitizer for effectively combating triple negative breast cancer with enhanced...

Area of Science:

• Biomedical Engineering
• Photodynamic Therapy
• Cancer Immunotherapy

Background:

• Photodynamic therapy (PDT) shows promise but has limitations in inhibiting cancer metastasis and invasion.
• Current PDT approaches often induce insufficient immune responses for complete cancer eradication.
• Indoleamine 2,3-dioxygenase (IDO) is a key immunosuppressive enzyme in the tumor microenvironment.

Purpose of the Study:

• To develop a novel photosensitizer (1-MT-Pc) by conjugating indoximod with zinc phthalocyanines (ZnPc).
• To evaluate the efficacy of 1-MT-Pc in enhancing PDT and immunotherapy against triple-negative breast cancer (TNBC).
• To assess the compound's ability to inhibit cancer cell metastasis and invasion.

Main Methods:

• Synthesis of 1-MT-Pc by conjugating indoximod with ZnPc.
• In vitro evaluation of intracellular uptake and reactive oxygen species (ROS) generation.
• Assessment of photocytotoxicity against TNBC cells and normal cells.
• In vivo studies on 4T1 tumor models to evaluate tumor inhibition, metastasis, and invasion.

Main Results:

• 1-MT-Pc demonstrated enhanced intracellular uptake and high ROS generation due to the indoximod moiety.
• Remarkable photocytotoxicity was observed against TNBC cells with negligible damage to normal cells.
• 1-MT-Pc significantly inhibited the metastasis and invasion of TNBC cells.
• Combined PDT and immunotherapy with 1-MT-Pc showed an elevated inhibitory effect on 4T1 tumor growth.

Conclusions:

• The novel photosensitizer 1-MT-Pc effectively overcomes limitations of traditional PDT by enhancing efficacy and reducing side effects.
• 1-MT-Pc holds potential as a dual-action agent for improved cancer treatment through combined photodynamic therapy and immunotherapy.
• This approach offers a promising strategy for inhibiting TNBC progression, including metastasis and invasion.